Since upregulation of serum IL-6 has been shown to be associated in SSc with disease activity, severity, disability, worse outcome, and reduced survival, targeting IL-6 may be particularly relevant in patients with early disease. This evidence concerns the gene IL6 and systemic sclerosis.